Recombinant human CD19-ligand protein as a potent anti-leukaemic agent

British Journal of Haematology

Volumn 153, Issue 1, 2011, Pages 15-23

  Uckun, Fatih M ^a,b,c   Sun, Lei ^c,d   Qazi, Sanjive ^e   Ma, Hong ^a,c   Ozer, Zahide ^a,c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c PARKER HUGHES INSTITUTE   (United States)

^d AutekBio   (China)

^e GUSTAVUS ADOLPHUS COLLEGE   (United States)

Author keywords

Apoptosis; B cell ontogeny; Gene expression; Leukaemia; Signalling

Indexed keywords

ANTILEUKEMIC AGENT; CD19 ANTIGEN; RECOMBINANT 54 KDA HIGH MOBILITY GROUP BOX PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER RESISTANCE; CELL LINEAGE; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOMA CELL; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLONING, MOLECULAR; GENE EXPRESSION PROFILING; HMGB PROTEINS; HUMANS; LIGANDS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECOMBINANT FUSION PROTEINS; SEQUENCE ALIGNMENT; TUMOR CELLS, CULTURED;

EID: 79952578696     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08583.x     Document Type: Article

References (37)

1. Aliahmad, P. & Kaye, J. (2008) Development of all CD4 T lineages requires nuclear factor TOX. Journal of Experimental Medicine, 205, 245-256.
2. Axcrona, K., Gray, D. & Leanderson, T. (1996) Regulation of B cell growth and differentiation via CD21 and CD40. European Journal of Immunology, 26, 2203-2207.
3. Bailey, L.C., Lange, B.J., Rheinhold, S.R. & Bunin, N.J. (2008) Bone marrow relapse in paediatric acute lymphoblastic leukemia. The Lancet Oncology, 9, 873-883.
4. Carter, R.H. & Fearon, D.T. (1992) Lowering the threshold for antigen receptor stimulation of B lymphocytes. Science, 256, 105-1067.
5. Chaouchi, N., Vazquez, A., Galanaud, P. & Leprince, C. (1995) B-cell antigen receptor mediated apoptosis. Importance of accessory molecules CD19 and CD22 and surface IgM cross-linking. Journal of Immunology, 154, 3096-3104.
6. Chen, C.L., Levine, A., Rao, A., O'Neill, K., Messinger, Y., Myers, D.E., Goldman, F., Hurvitz, C., Casper, J.T. & Uckun, F.M. (1999) Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies. Journal of Clinical Pharmacology, 39, 1248-1255.
7. Cheng, W.W.K., Das, D., Suresh, M. & Allen, T.M. (2007) Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochimica et Biophysica Acta, 1768, 21-29.
8. Chessells, J.M., Veys, P., Kempski, H., Henley, P., Leiper, A., Webb, D. & Hann, I.M. (2003) Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. British Journal of Haematology, 123, 396-405.
9. Cho, K., Wang, X., Nie, S., Chen, Z.G. & Shin, D.M. (2008) Therapeutic nanoparticles for drug delivery in cancer. Clinical Cancer Research, 14, 1310-1316.
10. la Cour, T., Gupta, R., Rapacki, K., Skriver, K., Poulsen, F.M. & Brunak, S. (2003) NESbase version 1.0: a database of nuclear export signals. Nucleic Acids Research, 31, 393-396.
11. Einsiedel, H.G., von Stackelberg, A., Hartmann, R., Fengler, R., Schrappe, M., Janka-Schaub, G., Mann, G., Hahlen, K., Gobel, U., Klingebiel, T., Ludwig, W.D. & Henze, G. (2005) Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia relapse study of the Berlin-Frankfurt-Munster Group 87. Journal of Clinical Oncology, 23, 7942-7950.
12. Engel, P., Zhou, L.J., Ord, D.C., Sato, S., Koller, B. & Tedder, T.F. (1995) Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity, 3, 39-50.
13. Fearon, D.T. & Carter, R.H. (1995) The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annual Review of Immunology, 13, 127-149.
14. Gaynon, P.S. (2005) Childhood ALL and relapse. British Journal of Haematology, 131, 579-587.
15. Ledbetter, J.A., Rabinovitch, P.S., June, C.H., Song, C.W., Clark, E.A. & Uckun, F.M. (1988) Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19. Proceedings of the National Academy of Sciences of the United States of America, 85, 1897-1901.
16. Malempati, S., Gaynon, P.S., Sather, H., La, M.K. & Stork, L.C. (2007) Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. Journal of Clinical Oncology, 25, 5800-5807.
17. + B cell lymphoma. Clinical Cancer Research, 6, 1302-1313.
18. Nickel, W. & Rabouille, C. (2009) Mechanisms of regulated unconventional protein secretion. Nature Reviews. Molecular Cell Biology, 10, 148-155.
19. O'Flaherty, E. & Kaye, J. (2003) TOX defines a conserved subfamily of HMG-box proteins. BMC Genomics, 4, 1-10.
20. O'Rourke, L., Tooze, R. & Fearon, D.T. (1997) Co-receptors of B lymphocytes. Current Opinion in Immunology, 9, 324-329.
21. Rhodes, D.R. (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18, 000 cancer gene expression profiles. Neoplasia, 9, 166-180.
22. Rickert, R.C., Rajewsky, K. & Rose, J. (1995) Impairement of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature, 376, 352-355.
23. Roy, A., Cargill, A., Love, S., Moorman, A.V., Stoneham, S., Lim, A., Darbyshire, P.J., Lancaster, D., Hann, I., Eden, T. & Saha, V. (2005) Outcome after first relapse in childhood acute lymphoblastic leukemia - lessons from the United Kingdom R2 trial. British Journal of Haematology, 130, 67-75.
24. Sato, S., Ono, N., Steeber, D.A., Pisetsky, D.S. & Tedder, T.F. (1996) CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. Journal of Immunology, 157, 4371-4378.
25. Sims, G.P., Rowe, D.C., Rietdijk, S.T., Herbst, R. & Coyle, A.J. (2010) HMG1 and RAGE in inflammation and cancer. Annual Review of Immunology, 28, 367-388.
26. Stanciu-Herrera, C., Morgan, C. & Herrera, L. (2008) Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in pre-B acute lymphoblastic leukemia cell lines. Leukemia Research, 32, 625-632.
27. Stone, M.J., Sausville, E.A., Fay, J.W., Headlee, D., Collins, R.H., Figg, W.D., Stetler-Stevenson, M., Jain, V., Jaffe, E.S., Solomon, D., Lush, R.M., Senderowicz, A., Ghetie, V., Schindler, J., Uhr, J.W. & Vitetta, E.S. (1996) A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood, 88, 1188-1193.
28. Tedder, T.F., Inaoki, M. & Sato, S. (1997) The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity, 6, 107-118.
29. Uckun, F.M. (1990) Regulation of human B-cell ontogeny (Review). Blood, 76, 1723-1733.
30. Uckun, F.M., Jaszcz, W., Ambrus, J.L., Fauci, A.S., Gajl-Peczalska, K., Song, C.W., Wick, M.R., Myers, D.E., Waddick, K. & Ledbetter, J.A. (1988) Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood, 71, 13-29.
31. Uckun, F.M., Burkhardt, A.L., Jarvis, L., Jun, X., Stealey, B., Dibirdik, I., Myers, D.E., Tuel-Ahlgren, L. & Bolen, J.B. (1993) Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. The Journal of Biological Chemistry, 268, 21172-21184.
32. Uckun, F.M., Evans, W.E., Forsyth, C.J., Waddick, K.G., Ahlgren, L.T., Chelstrom, L.M., Burkhardt, A., Bolen, J. & Myers, D.E. (1995) Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science, 267, 886-891.
33. Uckun, F.M., Messinger, Y., Chen, C.L., O'Neill, K., Myers, D.E., Goldman, F., Hurvitz, C., Casper, J.T. & Levine, A. (1999) Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clinical Cancer Research, 5, 3906-3913.
34. Uckun, F.M., Morar, S. & Qazi, S. (2006) Vinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukaemias. British Journal of Haematology, 135, 500-508.
35. Van Zelm, M.C., Reisli, I., van der Burg, M., Castano, D., van Noesel, C.J., van Tol, M.J., Woellner, C., Grimbacher, B., Patino, P.J., van Dongen, J.J. & Franco, J.L. (2006) An antibody-deficiency syndrome due to mutations in the CD19 gene. The New England Journal of Medicine, 354, 1901-1912.
36. Wilkinson, B., Chen, J.Y.-F., Hahn, P., Rufner, K.M. & Goularte, O.D. (2002) TOX: an HMG box protein implicated in the regulation of thymocyte selection. Nature Immunology, 3, 272-280.
37. Zhou, L.J., Smith, H.M., Waldschmidt, T.J., Schwarting, R., Daley, J. & Tedder, T.F. (1994) Tissue-specific expression of human CD19 gene in transgenic mice inhibits antigen-independent B lymphocyte development. Molecular and Cellular Biology, 14, 3884-3894.